PRCM
GLMD icon

Pine River Capital Management’s Galmed Pharmaceuticals GLMD Stock Holding History

Pine River Capital Management’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-55
Closed -$680K – 802
2014
Q3 		$680K Sell
55
-90
-62% -$984K 0.01% 700
2014
Q2 		$2.03M Buy
+145
New +$1.78M 0.03% 377

Other funds holding GLMD

6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $126M AUM 15.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CA
CapWealth Advisors Franklin, Tennessee $1.46B AUM 33.64% 1-Year Est. Return

Pine River Capital Management's GLMD Position: Q4 2014 in Review

Pine River Capital Management sold out of Galmed Pharmaceuticals (GLMD) in Q4 2014, closing a stake of 55 shares — an estimated $680K sold.

Pine River Capital Management first reported a position in GLMD in Q2 2014 and held it in 2 quarters. The position peaked at $2.03M in Q2 2014. 15 funds tracked by Wall St. Rank hold GLMD as of Q4 2014.

  • Pine River Capital Management reported no remaining Galmed Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Pine River Capital Management sold 55 Galmed Pharmaceuticals shares in Q4 2014, an estimated $680K.
  • Pine River Capital Management first reported a position in Galmed Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • Pine River Capital Management's Galmed Pharmaceuticals position peaked at $2.03M in Q2 2014.
  • 15 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2014.

Based on Pine River Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.